Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-Cell Lymphoma, Followed by Randomized Maintenance With Rituximab

Trial Profile

Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-Cell Lymphoma, Followed by Randomized Maintenance With Rituximab

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Rituximab (Primary) ; Carboplatin; Carmustine; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Ifosfamide; Melphalan
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CORAL
  • Most Recent Events

    • 30 Jan 2014 Accural to date is 100% as per United Kingdom Clinical Research Network record.
    • 07 Jun 2011 Final analysis results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jul 2010 Additional lead trial centre and investigator identified as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top